VAXCYTE, INC. Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs
VAXCYTE, INC. (PCVX) reported Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs of $45.81 million for the 12-month period ending 2022-12-31, per its 10-K filed 2023-02-27.
Discontinued
us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts · last filed 2023-02-27
- VAXCYTE, INC. adjustments to additional paid in capital, stock issued, issuance costs for the quarter ending 2020-09-30 was $72.00K.
- VAXCYTE, INC. adjustments to additional paid in capital, stock issued, issuance costs for fiscal 2022 was $45.81M.
| Period end | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs 3 month | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs 12 month |
|---|---|---|
| 2022-12-31 | $45.81M 10-K · filed 2023-02-27 | |
| 2020-09-30 | $72.00K 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |